Evidence map›Paper›PMID 40457387›Full record

SynthesisVirology journal2025

Unveiling protection: a meta-analysis of tixagevimab-cilgavimab prophylaxis in 28,950 transplant recipients and immunocompromised patients against COVID-19.

Mostafa Hossam El Din Moawad, Abdallah Abbas, Haneen Sabet, Mohamed Ahmed Zanaty, Abdullah Ashraf Hamad, Ayoub Rezkallah, Osama Ballut, Taha Fayad, Mona Mahmoud Elsakka, Francis Eshun and 1 more

Abstract readMeta-AnalysisReview
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mostafa Hossam El Din MoawadFaculty of Pharmacy Clinical Department, Alexandria University, Alexandria, Egypt.
Abdallah AbbasFaculty of Medicine, Al-Azhar University, Damietta, Egypt. abdallah.abdelmoneam.abbas@gmail.com.
Haneen SabetFaculty of Medicine, South Valley University, Qena, Egypt.
Mohamed Ahmed ZanatyFaculty of Medicine, South Valley University, Qena, Egypt.
Abdullah Ashraf HamadFaculty of Medicine, Menoufia University, Shibin El-Kom, Egypt.
Ayoub RezkallahFaculty of Medicine, Algiers University, Algiers, Algeria.
Osama BallutFaculty of Medicine, Kasr Alainy, Cairo University, Cairo, Egypt.
Taha FayadFaculty of Oral and Dental Medicine, Sinai University, North Sinai, Egypt.
Mona Mahmoud ElsakkaFaculty of Pharmacy, Damanhour University, Damanhour, Egypt.
Francis EshunCenter for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ, USA.
Hussien Ahmed H AbdelgawadCenter for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis meta-analysis addresses the efficacy and safety of tixagevimab-cilgavimab as pre-exposure prophylaxis against COVID-19 in immunocompromised patients, particularly during the Omicron variant surge. Given the limited vaccine response in this population, alternative prophylactic strategies are critical.

methodsFollowing PRISMA guidelines, we comprehensively searched electronic databases, including PubMed, Scopus, Web of Science, and Embase, up to June 22, 2024. We included studies assessing tixagevimab-cilgavimab's impact on SARS-CoV-2 infection rates, hospitalization, ICU admissions, and/or mortality among immunocompromised patients. Data synthesis and analysis were conducted using RevMan and Open-Meta Analyst software.

resultsAnalyzing data from 36 studies involving 28,950 patients, tixagevimab-cilgavimab significantly reduced SARS-CoV-2 infection rates by 4.37%, hospitalization by 0.8%, and mortality by 0.5%. Compared to no prophylaxis, the drug combination showed a notable reduction in SARS-CoV-2 infection (OR = 0.33, 95% CI: 0.22-0.50), hospitalization (OR = 0.24, 95% CI: 0.15-0.39), and mortality (OR = 0.33, 95% CI: 0.16-0.66), exhibiting a favorable safety and efficacy profile. During the Omicron surge, tixagevimab-cilgavimab consistently reduced infection risk (OR = 0.32, 95% CI: 0.17-0.58).

conclusionTixagevimab-cilgavimab offers a significant protective effect against COVID-19, including Omicron variants, in immunocompromised patients, underscoring its role as an effective pre-exposure prophylaxis. Future studies should further explore its efficacy across different SARS-CoV-2 variants and potential synergies with vaccination efforts.

Indexed as

Antibodies, Monoclonal, HumanizedAntiviral AgentsCOVID-19COVID-19 Drug TreatmentImmunocompromised HostPre-Exposure ProphylaxisTransplant RecipientsHospitalizationHumansSARS-CoV-2Antibodies, Monoclonal, HumanizedAntiviral Agents

Identifiers

PMID40457387
PMCPMC12131589

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.